Fill in this information to identify the case:				
Debtor	Eiger BioPharmaceuticals, Inc			
United States Ba	inkruptcy Court for the: Northern	District of Texas(State)		
Case number	24-80040	_		

Official Form 410

Proof of Claim 04/22

Read the instructions before filling out this form. This form is for making a claim for payment in a bankruptcy case. Do not use this form to make a request for payment of an administrative expense. Make such a request according to 11 U.S.C. § 503.

Filers must leave out or redact information that is entitled to privacy on this form or on any attached documents. Attach redacted copies or any documents that support the claim, such as promissory notes, purchase orders, invoices, itemized statements of running accounts, contracts, judgments, mortgages, and security agreements. **Do not send original documents;** they may be destroyed after scanning. If the documents are not available, explain in an attachment.

A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.

Fill in all the information about the claim as of the date the case was filed. That date is on the notice of bankruptcy (Form 309) that you received.

P	art 1: Identify the Clair	m			
1.	Who is the current creditor?	Sciensus International B.V. Name of the current creditor (the person or entity to be paid for this claim) Other names the creditor used with the debtor Healthcare At Home Netherlands B.V.			
2.	Has this claim been acquired from someone else?	✓ No Yes. From whom?			
3.	Where should notices and	Where should notices to the creditor be sent?	Where should payments to the creditor be sent? (if different)		
	payments to the creditor be sent? Federal Rule of Bankruptcy Procedure (FRBP) 2002(g)	See summary page	National Westminster Bank Plc 314 Chiswick High Street Chiswick, London W4 5TA, United Kingdom		
		Contact phone Contact email John.Bradshaw@sciensus.com (see summary page for notice party informat Uniform claim identifier for electronic payments in chapter 13 (if you us			
4.	Does this claim amend one already filed?	✓ No✓ Yes. Claim number on court claims registry (if known)	Filed on		
5.	Do you know if anyone else has filed a proof of claim for this claim?	No Yes. Who made the earlier filing?			

Official Form 410 Proof of Claim

Part 2:	Give Information Abo	out the Claim as of the Date the Case Was Filed
,	ou have any number	☑ No

6.	Do you have any number	per 🗹 No			
	you use to identify the debtor?	Yes. Last 4 digits of the debtor's account or any number you use to identify the debtor:			
7.	How much is the claim?	\$ 93,882.48 Does this amount include interest or other charges? No			
		Yes. Attach statement itemizing interest, fees, expenses, or other charges required by Bankruptcy Rule 3001(c)(2)(A).			
8.	What is the basis of the claim?	Examples: Goods sold, money loaned, lease, services performed, personal injury or wrongful death, or credit card. Attach redacted copies of any documents supporting the claim required by Bankruptcy Rule 3001(c). Limit disclosing information that is entitled to privacy, such as health care information. See summary page			
9.	Is all or part of the claim secured?	No			
10.	Is this claim based on a lease?	✓ No ✓ Yes. Amount necessary to cure any default as of the date of the petition.			
11.	Is this claim subject to a right of setoff?	✓ No Yes. Identify the property:			

Official Form 410 Proof of Claim

12. Is all or part of the claim	V	No				
entitled to priority under 11 U.S.C. § 507(a)?		Yes. Check a	all that apply:			Amount entitled to priority
A claim may be partly priority and partly nonpriority. For example, in some categories, the law limits the amount	_	Domesti 11 U.S.0	c support obligations (includ C. § 507(a)(1)(A) or (a)(1)(E	ing alimony and child supp	ort) under	\$
			3,350* of deposits toward poses for personal, family, or h			\$
entitled to priority.		days be	salaries, or commissions (ufore the bankruptcy petitioner is earlier. 11 U.S.C. § 50	is filed or the debtor's bus		\$
		Taxes or	penalties owed to governm	ental units. 11 U.S.C. § 50	07(a)(8).	\$
		Contribu	itions to an employee bene	fit plan. 11 U.S.C. § 507(a)(5).	\$
		Other. S	pecify subsection of 11 U.S	S.C. § 507(a)() that appl	ies.	\$
		* Amounts are	subject to adjustment on 4/01/2	5 and every 3 years after that f	or cases begun c	on or after the date of adjustment.
13. Is all or part of the claim		No				
entitled to administrative priority pursuant to 11 U.S.C. 503(b)(9)?		days before		of the above case, in whi	ch the goods h	ived by the debtor within 20 have been sold to the Debtor in g such claim.
		\$				
Part 3: Sign Below						
The person completing this proof of claim must sign and date it. FRBP 9011(b). If you file this claim electronically, FRBP 5005(a)(2) authorizes courts to establish local rules specifying what a signature is. A person who files a fraudulent claim could be fined up to \$500,000, imprisoned for up to 5 years, or both. 18 U.S.C. §§ 152, 157, and 3571.	☐ I a ☐ I a ☐ I a ☐ I a ☐ I declar ☐ I declar ☐ Execute	am the trustee am a guaranto stand that an ount of the cla examined the re under penal ed on date amsey Scofe and a first standard from the name of the first standard from t	r's attorney or authorized age, or the debtor, or their author, surety, endorser, or other authorized signature on this aim, the creditor gave the deinformation in this <i>Proof of lity</i> of perjury that the forego	orized agent. Bankruptcy Function of Claim serves as a both credit for any payment Claim and have reasonableing is true and correct. In and signing this claim Middle name	e 3005. an acknowledg ts received tow e belief that the	information is true and correct.
	Contact	nhono		Emoil		



Official Form 410 Proof of Claim

Verita (KCC) ePOC Electronic Claim Filing Summary

For phone assistance: Domestic (888) 733-1544 | International (310) 751-2638

For priorie assistance: Domestic (8		autoria: (010) 101 2000	
Debtor:			
24-80040 - Eiger BioPharmaceuticals, Inc District:			
Northern District of Texas, Dallas Division			
Creditor:	Has Supporting Docu	umentation:	
Sciensus International B.V.		g documentation successfully uploaded	
John Bradshaw	Related Document Statement:		
107 Station Street	Has Rolated Claims		
D	Has Related Claim:		
Burton-On-Trent, Staffordsh, DE14 1SZ	No		
United Kingdom	Related Claim Filed E	sy:	
Phone:	Filing Party:		
Phone 2:	Authorized age	ent	
Fax:			
Email:			
John.Bradshaw@sciensus.com			
Disbursement/Notice Parties:			
National Westminster Bank Plc	Ramsey Scofie	eld	
314 Chiswick High Street	1290 Avenue	of the Americas	
Chiswick, London, W4 5TA	New York, NY,	10104	
United Kingdom	United States	, 10104	
Phone:	Phone:		
Phone 2:	Phone 2:		
Fax:	Fax:		
E-mail:	E-mail:	10" 11 1	
DISBURSEMENT ADDRESS	ramsey.scotte	d@linklaters.com	
Other Names Used with Debtor:	Amends Claim:		
Healthcare At Home Netherlands B.V.	No		
	Acquired Claim:		
	No		
Basis of Claim:	Last 4 Digits:	Uniform Claim Identifier:	
Rejection damages for Distribution Agreement; postpetition external and internal legal costs	No		
Total Amount of Claim:	Includes Interest or C	Charges:	
93,882.48	No		
Has Priority Claim:	Priority Under:		
No Has Secured Claim:	Nature of Secured Ar		
No	Value of Property:	nount.	
Amount of 503(b)(9):			
No	Annual Interest Rate:	:	
Based on Lease:	Arrearage Amount:		
No	Basis for Perfection:		
Subject to Right of Setoff:	Amount Unsecured:		
No	, anount onsecured.		
Submitted By:			
Ramsey Scofield on 30-Oct-2024 2:05:50 p.m. Eastern Time	•		
Title:			
Senior Associate			
Company:			
Linklaters LLP			

Linklaters

Invoice

1002363386

Linklaters LLP One Silk Street London EC2Y 8HQ

Telephone: (0044) 207 456 2000 Facsimile: (0044) 207 456 2222 DX Box Number 10 CDE

29 October 2024

Sciensus Pharma Services Limited 107 Station Street Burton-On-Trent Staffordshire DE14 1SZ

Attn: Alistair Hodder

Fee Earner	Matter No	Client No
Mark Daniel	L-296829	10374963
In any further communications please quote this bill number	Date (VAT	POINT)

VAT Reg. No. GB918490990	R	ZE	Outside Scope
_	Α	Z	Other Zero Rated
TYPE OF SUPPLY - SALE	T	EX	Exempt
	ΙE	NT	Not Taxable
		FCNT	FC Not Taxable

GBP VAT **RATE General Competition** 15 May 2024 to 18 October 2024 **Professional charges** 54,974.17 20.0% VAT Analysis, GBP: Rate Net Value VAT 20% 54,974.17 10.994.83 Net Total 54.974.17 VAT 10,994.83 **Amount Now Due** 65,969.00 Please remit in Sterling. Authorised by Nicole Kar and signed by Linklaters LLP Unless otherwise agreed, this bill is payable within 30 days of invoice date Electronic payments should be remitted to for the account of Linklaters LLP. account number: IBAN: SWIFT: GBP sort code: SWIFT: **EUR sort code:** account number: IBAN: USD sort code: , account number: IBAN: SWIFT: Please send cheques to Linklaters LLP, One Silk Street, London, EC2Y 8HQ.

Linklaters LLP is a limited liability partnership registered in England and Wales with registered number OC326345. It is a law firm authorised and regulated by the Solicitors Regulation Authority. The term partner in relation to Linklaters LLP is used to refer to a member of Linklaters LLP or an employee or consultant of Linklaters LLP or any of its affiliated firms or entities with equivalent standing and qualifications. A list of the names of the members of Linklaters LLP together with a list of those non-members who are designated as partners and their professional qualifications is open to inspection at its registered office, One Silk Street, London EC2Y 8HQ or on www.linklaters.com and such persons are either solicitors, registered foreign lawyers or European lawyers. Please refer to www.linklaters.com/regulation for important information on our regulatory position.

Please quote the bill number with your payment. Send any remittance advices to remittanceadvice@linklaters.com

Rejection damages claim against Eiger Pharmaceuticals and/or Eiger Bio Europe to be filed on October 30, 2024 in the amount of US Dollars \$93,882.48.

Time engaged by Senior Legal Counsel for Sciensus Aude Ocasi	Hours	
Weekly in internal call with Finance (Vass) and MD-Rare (Tony) to manage issues resulting from Eiger bankruptcy. 2 hours per week for 17 weeks, from date of notice of bankruptcy (1 April 2024) to signing new agreement with Sentanyl (2nd August 2024).	34	
Strategy alignment with US lawyers and Sciensus Legal Director. Average 1 hour per week 2 weeks for 17 weeks, from date of notice of bankruptcy (1 April 2024) to signing new agreement with Sentanyl (2nd August 2024).	8.5	
Review of bankruptcy documentation	10	
Drafting and negotiation of two settlement letters for setting off amounts.	10	
Briefing notes to leadership team	5	
Negotiation of Amendment to Sentynl Distribution Agreement to add Zokinvy in scope.	20	
Total	87.5	
Hourly rate	£70.21	
Claim (GBP)	6,143.38	
Claim (USD)		8,000.74
Linklaters Costs (inc VAT)		
Claim (GBP)	65,969.00	
Claim (USD)		85,881.74
<u>Total claim USD</u>		93,882.48

Scofield, Ramsey

From: Alistair Hodder <

Sent: Wednesday, October 30, 2024 10:59 AM

To: Scofield, Ramsey

Subject: RE: INTERNAL SCIENSUS ONLY - Sciensus/ Eiger - Post petition claims [Linklaters-

LLU.FID246067]

Attachments: Eiger bankruptcy Sciensus cost claim 30.10.24.docx; Exchange calculation 1.jpg;

Exchange calculation 2.jpg; L-296829_1002363386.pdf

Hi Ramsey

I've completed the costs calculations and currency conversions (using my Revolute banking app, just now) for our claim. Please see the attached.

As discussed, this email to confirm you are authorised as our attorney to file and sign the claim forms against Eiger Pharmaceuticals and Eiger Bio Europe on behalf of Sciensus International BV.

Should you need anything else from me, do please let me know; and if you need to call its +

s +

With best regards and thanks, Alistair

Alistair Hodder

Interim Senior Legal Counsel

Sciensus.com







IMPORTANT PLEASE READ

Sciensus and logo are registered trademarks. Sciensus Pharma Services Limited registered in England under Company No. 02759609. Registered office: 107 Station Street, Burton upon Trent, Staffordshire, DE14 1SZ, UK.

e-mail: generalenquiries@sciensus.com

This e-mail and the information that it contains may contain private, confidential, or privileged information. Access is authorised by the intended recipient only. If you are not the intended recipient please notify the sender immediately and do not disclose the contents to any other person, use it for any purpose or store or copy the information in any medium.

Copyright and other intellectual property rights in this e-mail and any attachments to this e-mail created by Sciensus Pharma Services Limited belongs to Sciensus Pharma Services Limited, and as the author Sciensus Pharma Services Limited asserts the right to be identified as such and object to any misuse.

Please note that any attachments to this e-mail have been checked for viruses but please rely on your own virus checker and procedures.

Any liability (in negligence, contract or otherwise) arising from any third party taking any action, or refraining from taking any action, on the basis of any of the information contained in this e-mail is excluded.

This email has been scanned by the Mimecast service	

IMPORTANT PLEASE READ

Sciensus and logo are registered trademarks. Sciensus Pharma Services Limited registered in England under Company No. 02759609. Registered office: 107 Station Street, Burton upon Trent, Staffordshire, DE14 1SZ, UK

e-mail: generalenquiries@sciensus.com

This e-mail and the information that it contains may contain private, confidential, or privileged information. Access is authorised by the intended recipient only. If you are not the intended recipient please notify the sender immediately and do not disclose the contents to any other person, use it for any purpose or store or copy the information in any medium.

Copyright and other intellectual property rights in this e-mail and any attachments to this e-mail created by Sciensus Pharma Services Limited, and as the author Sciensus Pharma Services Limited asserts the right to be identified as such and object to any misuse.

Please note that any attachments to this e-mail have been checked for viruses but please rely on your own virus checker and procedures.

Any liability (in negligence, contract or otherwise) arising from any third party taking any action, or refraining from taking any action, on the basis of any of the information contained in this e-mail is excluded.